Business Context and Reporting Period
Company: Nuvelo, Inc. (formerly Hyseq, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Nuvelo is a biopharmaceutical company focused on the discovery, development, and commercialization of novel products for acute cardiovascular indications and cancer. The company operates two primary segments: Nuvelo Inc. (therapeutic drug development) and Callida Genomics, Inc. (sequencing-by-hybridization technology).
Key Developments: In January 2003, Nuvelo merged with Variagenics, Inc. to accelerate biotherapeutic development. The company has three primary drug candidates in development: alfimeprase (Phase 2), rNAPc2 (Phase 2a), and ARC183 (preclinical/IND anticipated mid-2004).
Key Financial Metrics
| Metric (in thousands) | 2003 | 2002 |
|---|---|---|
| Contract Revenues | $2,290 | $26,433 |
| Total Operating Expenses | $51,532 | $70,368 |
| Net Loss | $(50,187) | $(44,978) |
| Loss Per Share (Basic & Diluted) | $(2.37) | $(6.24) |
| Cash and Cash Equivalents (Year End) | $13,141 | $2,225 |
| Short-Term Investments | $21,048 | $0 |
| Total Assets | $57,809 | $27,072 |
| Working Capital | $25,772 | $(20,728) |
| Accumulated Deficit | $(203,559) | $(153,372) |
Liquidity Note: As of December 31, 2003, the company held approximately $34.2 million in cash, cash equivalents, and short-term investments. In March 2004 (subsequent to year-end), the company completed a public offering raising approximately $70.3 million net.
Material Changes vs. Prior Period
- Revenue Decline: Contract revenues dropped 91% to $2.3 million from $26.4 million in 2002. This was primarily due to the completion of the BASF collaboration in January 2003 (decreasing revenue by $21.9 million) and the completion of deferred revenue recognition from the Affymetrix settlement.
- Expense Reduction: Total operating expenses decreased by $18.9 million to $51.5 million. Research and development expenses fell by $17.1 million, driven by the early completion of the BASF agreement and lease termination savings, partially offset by costs associated with the Variagenics merger.
- Balance Sheet Improvement: Total assets more than doubled to $57.8 million, largely due to the Variagenics merger which contributed $25.7 million in net cash and the October 2003 public offering. Working capital improved from a deficit of $20.7 million in 2002 to a positive $25.8 million in 2003.
- Net Loss Increase: Net loss increased to $50.2 million from $45.0 million, reflecting the continued investment in clinical trials despite cost-cutting measures.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Pipeline:
- Alfimeprase: Phase 2 trials for acute peripheral arterial occlusion (PAO) and catheter occlusion are ongoing. Enrollment for the PAO trial is projected to complete in March/April 2004, with a potential Phase 3 initiation in the second half of 2004.
- rNAPc2: Licensed from Dendreon in February 2004. Phase 2a trials for acute coronary syndromes are underway.
- ARC183: Collaboration with Archemix signed in January 2004. IND filing anticipated mid-2004, with Phase 1 trials expected in the second half of 2004.
- Capital Needs: Management expects to continue incurring significant net losses as clinical development costs increase. The company anticipates needing to raise additional capital to fund operations and clinical trials.
Risks and Contingencies
- Profitability: The company has never been profitable and has an accumulated deficit of $203.6 million. There is no assurance it will ever achieve profitability.
- Regulatory Approval: All products require FDA approval. Clinical trials may fail to demonstrate safety or efficacy, or regulatory approval may be delayed or denied.
- Collaboration Dependence: Success depends on partnerships with Amgen, Archemix, and Dendreon. Disputes or terminations could halt development.
- Intellectual Property: The company faces risks regarding the enforceability of its patents and potential infringement claims by third parties.
- Legal Proceedings: The company is defending a securities class action lawsuit inherited from Variagenics regarding its 2000 IPO. A settlement is being negotiated, but final terms are not yet executed.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34.2 million year-end cash balance plus the $70.3 million raised in March 2004 to fund the projected increase in clinical trial costs for 2004 and beyond.
- Clinical Milestones: Monitor the completion dates and interim analysis results for the alfimeprase Phase 2 trials (PAO and catheter occlusion) scheduled for March/April 2004.
- Collaboration Terms: Review the specific milestone payment obligations and cost-sharing structures in the new agreements with Archemix (ARC183) and Dendreon (rNAPc2).
- Legal Settlement: Track the finalization of the Variagenics securities class action settlement to assess potential liability exposure.
- Revenue Sustainability: Assess the ability to generate revenue from new collaborations or government grants given the cessation of the major BASF revenue stream.